Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Min Y. Teo"'
Autor:
Jonathan A. Coleman, Wesley Yip, Nathan C. Wong, Daniel D. Sjoberg, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Eugene K. Cha, Timothy F. Donahue, Eugene J. Pietzak, A. Ari Hakimi, Kwanghee Kim, Hikmat A. Al-Ahmadie, H. Alberto Vargas, Ricardo G. Alvim, Soleen Ghafoor, Nicole E. Benfante, Anoop M. Meraney, Steven J. Shichman, Jeffrey M. Kamradt, Suresh G. Nair, Angelo A. Baccala, Paul Palyca, Bradley W. Lash, Muhammad A. Rizvi, Scott K. Swanson, Antonio F. Muina, Andrea B. Apolo, Gopa Iyer, Jonathan E. Rosenberg, Min Y. Teo, Dean F. Bajorin
Publikováno v:
Journal of Clinical Oncology. 41:1618-1625
PURPOSE Neoadjuvant chemotherapy (NAC) has proven survival benefits for patients with invasive urothelial carcinoma of the bladder, yet its role for upper tract urothelial carcinoma (UTUC) remains undefined. We conducted a multicenter, single-arm, ph
Autor:
Vadim S. Koshkin, Bernadett Szabados, Daniel Castellano, Matthew D. Galsky, Petros Grivas, Lucia Carril-Ajuria, Min Y. Teo, Daniele Raggi, Guru Sonpavde, Parissa Alerasool, Thomas Powles, Lillian Werner, Jacob Gaines, Xiao X. Wei, Ravindran Kanesvaran, Joaquim Bellmunt, Jonathan E. Rosenberg, Andrea Necchi, Noah M. Hahn, Rana R. McKay, Laura Morrison, Pedro Isaacsson Velho
Publikováno v:
J Urol
PURPOSE: Current first-line treatment options in patients with metastatic urothelial carcinoma (mUC) unfit to receive cisplatin-containing chemotherapy include PD-1/L1 inhibitors and carboplatin-containing chemotherapy. However, the optimal sequencin
Autor:
Ziyu Chen, Timothy N. Clinton, Soonbum Park, Andrew T. Lenis, Mark Donoghue, Jonathan E. Rosenberg, Bajorin F. Dean, Min Y. Teo, Bernard H. Bochner, Irina Ostrovnaya, Eugene J. Pietzak, Gopakumar V. Iyer, Sizhi Gao, Wenhuo Hu, Michael M. Shen, Michael F. Berger, Hikmat A. Al-Ahmadie, Corinne T. Abate-Shen, David B. Solit
Publikováno v:
Cancer Research. 82:1596-1596
Background: Precision oncology relies on the accurate molecular characterization of individual cancer patients at the time of treatment initiation. However, tumor molecular profiles are not static, and cancers continually evolve because of ongoing mu
Autor:
Min Y. Teo, S. Cushen, Derek G. Power, Aoife M. Ryan, Michael M. Maher, Ray McDermott, Kathleen O'Sullivan, Peter MacEneaney
Publikováno v:
American Journal of Clinical Oncology. 40:47-52
Sunitinib is a standard first-line option for metastatic renal cell carcinoma (mRCC). Body composition is a prognostic factor in cancer patients and patients with loss of skeletal muscle mass and fat-free mass (FFM) are prone to dose-limiting toxicit
Publikováno v:
The Oncologist. 17:1450-1460
Learning Objectives After completing this course, the reader will be able to: Summarize trends in the treatment of older women with ovarian cancer.Describe the potential value of performing a geriatric assessment prior to treatment in older women wit